<DOC>
	<DOCNO>NCT00724815</DOCNO>
	<brief_summary>This study randomize , parallel group , double-blind , placebo control design compare efficacy tolerability NP101 placebo iontophoretic transdermal patch . The primary objective study assess proportion subject headache pain free two hour patch activation . Key secondary objective include : 1 . The proportion subject nausea free two hour patch activation . 2 . The proportion subject photophobia free two hour patch activation . 3 . The proportion subject phonophobia free two hour patch activation .</brief_summary>
	<brief_title>The Efficacy Tolerability NP101 Patch Treatment Acute Migraine</brief_title>
	<detailed_description>Subjects stay study treat one migraine headache study patch two month randomization , whichever occur first . During migraine headache , subject rat baseline headache pain severity Migraine Study Diary use 4-point scale ( 0 = none , 1 = mild , 2 = moderate , 3 = severe ) apply study patch score 2 3 ( i.e. , qualify migraine headache ) . In addition headache pain severity , subject also record presence absence aura , nausea , phonophobia , photophobia , well location headache ( unilateral bilateral ) whether headache increase movement .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject adult male female , age range 18 year 65 year . Subject diagnosis migraine headache , without aura , define ICDHII diagnosis make age 50 . Subject typically experience moderate severe headache migraine attack . Subject least one year history migraine . Subject judge good health , base result medical history , physical examination , vital sign , ECG laboratory profile . Female subject childbearing potential must negative pregnancy test screen prior randomization . Subject must negative drug screen . Subject must capable read understand either English Spanish subject information material . Be able successfully apply practice patch , carryout subject procedure , able voluntarily sign date IRB approve IC agreement . Subject acceptable patch application site ( upper arm ) relatively hair free scar , tattoo , scratch , bruise . Subject plan start , stop , change treatment dose prophylactic antimigraine treatment within 3 month prior subject ' study randomization date final visit . Subject plan start , stop , change treatment dose follow within 3 month prior subject ' study randomization date final visit : anxiolytic , lithium mood stabilizer , hypnotic antipsychotic . Subject le one migraine per month six migraine per month , 15 headache day per month three month prior randomization . Subject suspect confirmed cardiovascular disease contraindicates study participation . Subject history epilepsy condition associate lowered seizure threshold . Subject Raynaud 's disease . Subject history basilar hemiplegic migraine . Subject current diagnosis major depressive disorder per DSM IV R. Subject history ( within 1 year ) current evidence drug alcohol abuse dependence . Subject unwilling discontinue use serotonin agonist ( triptans ) , except study patch , Final Visit . Subject take SSRI 's , SNRI 's , TCA 's , MAOI 's preparation contain St. John 's Wort within 1 month prior screen and/or plan start medication study . Subject unwilling discontinue use PD5 inhibitor Final Visit . Subject take ergot medication within 7 day prior Randomization and/or unwilling discontinue use Final Visit . Subject history significant allergy hypersensitivity component study patch . Subject generalized skin irritation disease include eczema , psoriasis , melanoma , contact dermatitis . Subject clinically significant abnormal laboratory parameter , vital sign ECG parameter . Subject know hepatitis B , hepatitis C HIV positive . Subject hepatic dysfunction base laboratory result opinion Investigator subject 's history , physical examination laboratory test suggest hepatic dysfunction . Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception study period 30 day follow dosing . Subject known history failure respond sumatriptan . Subject participate clinical study within 30 day screen plan participate another clinical study . Subject previously enrol NP101007 Subject electrically sensitive electrically sensitive support system ( e.g. , pacemaker ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>